Results 1 to 10 of about 5,432 (70)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration

Scientific Reports, 2023
Accumulating evidence suggests that metabolic demands of the regenerating liver are met via lipid metabolism and critical regulators of this process. As such, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) critically affect hepatic ...
Markus Ammann, Jonas Santol, David Pereyra, Tamara Kalchbrenner, Tanja Wuerger, Johannes Laengle, Rory L. Smoot, Wolfgang Hulla, Friedrich Laengle, Patrick Starlinger   +9 more
doaj   +1 more source

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects

Journal of Diabetes Investigation, 2020
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those
Takaaki Murakami, Hiroyuki Fujimoto, Naotaka Fujita, Keita Hamamatsu, Daisuke Yabe, Nobuya Inagaki   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1

JACC: Basic to Translational Science, 2016
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
Joel P. Giblett, BM, BSc, Sophie J. Clarke, BSc, David P. Dutka, MD, Stephen P. Hoole, MA, DM   +3 more
doaj   +1 more source

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2017
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj   +1 more source

Glucagon-like peptide 1 (GLP-1)

Molecular Metabolism, 2019
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying ...
T.D. Müller, B. Finan, S.R. Bloom, D. D'Alessio, D.J. Drucker, P.R. Flatt, A. Fritsche, F. Gribble, H.J. Grill, J.F. Habener, J.J. Holst, W. Langhans, J.J. Meier, M.A. Nauck, D. Perez-Tilve, A. Pocai, F. Reimann, D.A. Sandoval, T.W. Schwartz, R.J. Seeley, K. Stemmer, M. Tang-Christensen, S.C. Woods, R.D. DiMarchi, M.H. Tschöp   +24 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

International Journal of Endocrinology, 2015
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang, Huan Liu, Jiaqi Chen, Yan Li, Shen Qu   +4 more
doaj   +1 more source

Equine glucagon-like peptide-1 receptor physiology [PDF]

PeerJ, 2018
Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased ...
Murad H. Kheder, Simon R. Bailey, Kevin J. Dudley, Martin N. Sillence, Melody A. de Laat   +4 more
doaj   +2 more sources

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice

Journal of Cardiovascular Development and Disease, 2023
Background: Calcific aortic valve disease (CAVD) is a significant cause of morbidity and mortality among elderly people. However, no effective medications have been approved to slow or prevent the progression of CAVD.
Yangzhao Zhou, Zhaoshun Yuan, Min Wang, Zhiyuan Zhang, Changming Tan, Jiaolian Yu, Yanfeng Bi, Xiaobo Liao, Xinmin Zhou, Md Sayed Ali Sheikh, Dafeng Yang   +10 more
doaj   +1 more source

Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition

World Nutrition, 2019
There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj   +1 more source